Smith & Nephew (LON: SN.) shares rose more than 5% on Wednesday after the medical technology firm reported a 3.1% underlying revenue increase for the first quarter of 2025, driven by operational improvements and recent product launches.
Group revenue for the period ended 29 March totalled $1.41 billion, up from $1.39 billion in Q1 2024.
Reported growth was 1.6%, reflecting a 150 basis point foreign exchange headwind. The company said it was a “good start to the year,” reinforcing confidence in its full-year outlook.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
Chief Executive Officer Deepak Nath credited the company’s “12-Point Plan” for delivering improved performance.
“Key platforms, such as CORI, EVOS, REGENETEN and our Negative Pressure Wound Therapy portfolio all delivered strong double-digit growth,” Nath said, noting continued momentum from innovation and new product launches.
The company revealed that Orthopaedics delivered 3.2% underlying revenue growth, supported by a sustained improvement in U.S. hip and knee implants. Sports Medicine & ENT posted 2.4% underlying growth, with strong demand in established markets partly offset by weakness in China.
Advanced Wound Management grew 3.8%, led by foams and negative pressure wound therapy.
Despite ongoing tariff-related uncertainty, Smith & Nephew reiterated its 2025 guidance. The company continues to expect around 5% underlying revenue growth and a trading profit margin between 19% and 20%.
Headwinds from China remained a factor, but the company believes their impact has “now passed their peak.”
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading and investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!
- IG Top-tier regulation – Read our Review
- eToro Wide range of instruments available to trade – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
